- Home
- TMCI
as 07-26-2024 4:00pm EST
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers, and hospitals.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | PONTE VEDRA |
| Market Cap: | 409.9M | IPO Year: | 2021 |
| Target Price: | $10.42 | AVG Volume (30 days): | 841.7K |
| Analyst Decision: | Hold | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.88 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.92 - $23.34 | Next Earning Date: | 08-06-2024 |
| Revenue: | $196,031,000 | Revenue Growth: | 26.48% |
| Revenue Growth (this year): | 11.97% | Revenue Growth (next year): | 11.88% |
Stock Insider Trading Activity of Treace Medical Concepts Inc. (TMCI)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Treace John T. | TMCI | Chief Executive Officer | Jun 11 '24 | Buy | $5.88 | 45,000 | $264,600.00 | 6,388,095 | SEC Form 4 |
| TREACE JAMES T | TMCI | Director | May 29 '24 | Buy | $5.20 | 25,000 | $130,062.50 | 1,114,441 | SEC Form 4 |
| TREACE JAMES T | TMCI | Director | May 28 '24 | Buy | $5.07 | 50,000 | $253,475.00 | 1,089,441 | SEC Form 4 |
| MOTT RICHARD W | TMCI | Director | May 24 '24 | Buy | $5.19 | 18,000 | $93,501.00 | 1,072,944 | SEC Form 4 |
| MOTT RICHARD W | TMCI | Director | May 22 '24 | Buy | $4.99 | 12,100 | $60,424.98 | 1,054,944 | SEC Form 4 |
| Treace John T. | TMCI | Chief Executive Officer | May 17 '24 | Buy | $5.56 | 100,000 | $556,170.00 | 6,343,095 | SEC Form 4 |
| Treace John T. | TMCI | Chief Executive Officer | May 14 '24 | Buy | $5.12 | 150,000 | $767,805.00 | 6,243,095 | SEC Form 4 |
| Kiernan Jane E | TMCI | Director | May 14 '24 | Buy | $5.17 | 19,356 | $100,000.84 | 24,941 | SEC Form 4 |
| BAKEWELL JOHN K | TMCI | Director | May 10 '24 | Buy | $4.57 | 130,000 | $594,620.00 | 135,048 | SEC Form 4 |
| Treace John T. | TMCI | Chief Executive Officer | May 10 '24 | Buy | $4.58 | 150,000 | $686,880.00 | 5,943,095 | SEC Form 4 |
| Treace John T. | TMCI | Chief Executive Officer | May 10 '24 | Buy | $4.56 | 150,000 | $683,490.00 | 6,093,095 | SEC Form 4 |
| Jain Deepti | TMCI | Director | May 10 '24 | Buy | $4.50 | 25,000 | $112,567.50 | 31,235 | SEC Form 4 |
| MOTT RICHARD W | TMCI | Director | May 10 '24 | Buy | $4.57 | 83,198 | $379,848.79 | 990,951 | SEC Form 4 |
| MOTT RICHARD W | TMCI | Director | May 10 '24 | Buy | $4.38 | 36,802 | $161,089.71 | 1,027,753 | SEC Form 4 |
| TREACE JAMES T | TMCI | Director | May 10 '24 | Buy | $4.53 | 83,000 | $376,023.20 | 894,441 | SEC Form 4 |
| TREACE JAMES T | TMCI | Director | May 10 '24 | Buy | $4.54 | 145,000 | $657,981.00 | 1,039,441 | SEC Form 4 |
| TREACE JAMES T | TMCI | Director | Nov 15 '22 | Sell | $20.12 | 46,500 | $935,580.00 | 1,039,941 | SEC Form 4 |
| TREACE JAMES T | TMCI | Director | Nov 15 '22 | Sell | $21.18 | 1,600 | $33,890.08 | 1,038,341 | SEC Form 4 |
| TREACE JAMES T | TMCI | Director | Nov 15 '22 | Sell | $21.97 | 200 | $4,394.00 | 1,038,141 | SEC Form 4 |
| TREACE JAMES T | TMCI | Director | Nov 15 '22 | Sell | $24.02 | 1,700 | $40,828.39 | 1,036,441 | SEC Form 4 |
Latest Treace Medical Concepts Inc. News
TMCI Breaking Stock News: Dive into TMCI Ticker-Specific Updates for Smart Investing
Argus Research
13 hours ago
Daily – Vickers Top Insider Picks for 07/26/2024
Argus Research
2 days ago
Daily – Vickers Top Insider Picks for 07/25/2024
Argus Research
3 days ago
Daily – Vickers Top Insider Picks for 07/24/2024
Argus Research
4 days ago
Daily – Vickers Top Insider Picks for 07/23/2024
Argus Research
5 days ago
Daily – Vickers Top Insider Picks for 07/22/2024
Argus Research
7 days ago
Daily – Vickers Top Insider Picks for 07/19/2024
Argus Research
7 days ago
Daily – Vickers Top Insider Picks for 07/19/2024
GlobeNewswire
8 days ago
Treace to Report Second Quarter 2024 Financial Results on August 6, 2024
Compare TMCI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TMCI Treace Medical Concepts Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.